drugset / Trial / NCT05610332
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the clinical efficacy of albumin paclitaxel combined with carelizumab and FLOT in the neoadjuvant treatment of locally advanced gastric cancer with different immune types
Timeline
- Start
- 2022-11-01
- Primary completion
- 2024-11-01
- Completion
- 2027-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin paclitaxel | Unknown | 260 mg/m2 | Intravenous |
| Subject | Calcium folinate | Unknown | 200 mg/m2 | Intravenous |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Docetaxel | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2600 mg/m2 | Intravenous |